Skip to content
directory image

AVAHO recognizes the importance of our members' connection to their Industry partners. In order to facilitate ongoing communications between AVAHO members and the industry representatives who may help with treatment options and questions, we created an industry directory.

This directory will allow companies to share a primary federal contact, a medical science liaison contact, and website information about your company.

Click the link below to share and update your company information.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

AbbVie Inc.

About Us

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas.


1 North Waukegan Road
North Chicago, IL 60064
(800) 240-1043
abbvie.com

Primary Contacts

Shirley Garza-Gongora
Federal Account Executive
(210) 478-6074
shirley.garzagongora@abbvie.com

Ashley Polce
Federal Medical Outcomes Science Liaison
(314) 439-6040
ashley.polce@abbvie.com

Products or Services

VENCLEXTA is a BCL-2 inhibitor indicated:

  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

LUPRON DEPOT (leuprolide acetate for depot suspension):

  • Is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostatic cancer.

Amgen

About Us

Amgen harnesses the best of biology and technology to make people’s lives easier, fuller, and longer. We draw upon our deep knowledge of science to push beyond what’s known today. With roots in the biotech revolution, we are one of the world’s leading independent biotech companies – fighting the toughest diseases and helping millions of people globally.


1 Amgen Center Drive
Thousand Oaks, CA 91320
(703) 955-6090
amgen.com

Primary Contacts

Keith Knowles
National Account Manager
(703) 955-6090
kknowles@amgen.com

Dan Flores, PharmD
Medical Value and Access Director
(973) 362-8300
danflore@amgen.com

Products or Services

ACTIMMUNE® (interferon gamma 1-b)
AIMOVIG® (erenumab-aooe)
AMJEVITA® (adalimumab-atto)
ARANESP® (darbepoetin alfa)
AVSOLA® (infliximab-axxq)
BLINCYTO® (blinatumomab)
BUPHENYL® (sodium phenylbutyrate)
CORLANOR® (ivabradine)
EPOGEN® (epoetin alfa)
ENBREL® (etanercept)
EVENITY® (romosozumab-aqqg)
IMLYGIC® (talimogene laherparepvec)
KANJINTI® (trastuzumab-anns)
KRYSTEXXA® (pegloticase)
KYPROLIS® (carfilzomib)
LUMAKRAS® (sotorasib)

MVASI® (bevacizumab-awwb)
NEULASTA® (pegfilgrastim)
NEUPOGEN® (filgrastim)
NPLATE® (romiplostim)
OTEZLA® (apremilast)
PARSABIV® (etelcalcetide)
PROCYSBI® (crysteamine bitartrate)
PROLIA® (denosumab)
RAVICTI® (glycerol phenylbutryrate)
REPATHA® (evolocumab)
RIABNI® (rituximab-arrx)
SENSIPAR® (cinacalcet)
TAVNEOS® (avacopan)
TEZSPIRE® (tezepelumab-ekko)
VECTIBIX® (panitumumab)
XGEVA® (denosumab)

AVEO Oncology, an LG Chem Company

326085324_1016263219331659_5983293897572422626_n

About Us

AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 19, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.


One Marina Park Drive, 12th floor
Boston, MA 02210
(857) 400-0101
aveooncologycom

Primary Contacts

Samuel Villa
Senior Director, Federal Markets
(716) 480-7456
svilla@aveooncology.com

Sherry Nelson, PharmD, BCOP
Senior Medical Science Liaison
(919) 696-3902
snelson@aveooncology.com

Bayer Healthcare

69-WQCQU_400x400

About Us

Science for a better life.


1 Bayer Blvd
Whippany, NJ 07981
(862) 404-3000
bayer.com

Primary Contacts

Eric Patterson
National Account Director, VA
(608) 301-7405
eric.patterson@bayer.com

Dr. Jay Jhaveri
Medical Director, US Oncology
(516) 721-7568
jay.jhaveri@bayer.com

Products or Services

Nubeqa (darolutamide)
Xofigo (Radium 223)
Stivarga (regorafenib)
Nexavar (sorafenib)
Vitrakvi (larotrectinib)

BeiGene

beigene_sq_logo

About Us

Build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.


2955 Campus Drive, 2nd Floor
San Mateo, CA 94403
(615) 414-6211
beigene.com

Primary Contacts

Eric Kite
National Account Director
(615) 414-6211
eric.kite@beigene.com

Lee Ding
Sr. HEOR Field Director
(628) 222-5293
lee.ding@beigene.com

Products or Services

BRUKINSA is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Waldenström's macroglobulinemia (WM).
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
  • Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.

Blueprint Medicines

blueprint-medicines_sq_logo

About Us

Blueprint Medicines aims to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible.


45 Sidney St
Cambridge, MA 02139
(617) 374-7580
blueprintmedicines.com

Primary Contacts

Dean Petree
National Account Executive
(612) 669-9731
dpetree@blueprintmedicines.com

Rahul Kalathiya
Senior Medical Science Liaison
(859) 312-9053
rkalathiya@blueprintmedicines.com

Products or Services

AYVAKIT® (avapritinib) is a prescription medicine used to treat adults with:

  • A certain type of stomach, bowel, or esophagus cancer called gastrointestinal stromal tumor (GIST) that cannot be treated with surgery or that has spread to other parts of the body (metastatic), and that is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes. Your healthcare provider will perform a test to make sure that you have this abnormal PDGFRA gene and that AYVAKIT is right for you.

 

  • Advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). AYVAKIT is not recommended for the treatment of AdvSM in people with low platelet counts (less than 50 x 109/L).
  • Indolent systemic mastocytosis (ISM). AYVAKIT is not recommended in people with low platelet counts (less than 50 X 109/L).

Caris Life Sciences

7e09703fc3526e7b3703f1e6a94d5ea8

About Us

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies informed by massive amounts of big data, we are revolutionizing healthcare to provide physicians and patients with the highest quality information about their disease – from detecting it early and determining how best to treat it, to developing the next wave of novel therapies.


4610 South 44th Place
Phoenix, AZ 85040
(888) 979-8669
carislifesciences.com

Primary Contacts

Brian Cilinski
VP - National Accounts
(910) 297-7452
bcilinski@carisls.com

Hani El Shawa
AVP - Molecular Science Liaison
(470) 606-2220
helshawa@carisls.com

Products and Services

With the promise of precision medicine becoming a reality, broad molecular profiling has become standard of care for many cancer types – and is required for certain therapies. More than ever, oncologists need a trusted profiling partner to provide reliable, high-quality molecular profiling information to guide precise and individualized treatment decisions. Our comprehensive molecular profiling approach precisely analyzes DNA, RNA, and protein biomarkers, revealing the highest quality molecular blueprint for evidence-based selection of the most appropriate cancer therapy. In addition to comprehensive molecular profiling, Caris has innovated industry-leading artificial intelligence algorithms that predict patient responses to standard treatments, such as immunotherapy or chemotherapy, based on their personalized molecular profile. Caris is the original, most experienced comprehensive molecular profiling laboratory, and we have optimized our systems to provide industry-leading reports, service and turnaround time.

Caris molecular profiling helps oncologists:
Navigate among therapies with potential benefit
Identify therapies that may not have been considered
Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs)
Match patients to clinical trials

Caris offers both a tissue-based and liquid (blood) assay. Please visit our website at www.carislifesciences.com for a full list of offerings.

Deciphera Pharmaceuticals

deciphera_sq_logo

About Us

One Mission, Inspired by Patients: Defeat Cancer.


200 Smith Street
Waltham, MA 02451
(781) 209-6400

Primary Contacts

Ben Stutzman
Associate Director Market Access
(361) 549-8937
bstutzman@deciphera.com

Nicholas Zeringo
Associate Scientific Director, Medical Affairs
(856) 912-1181
nzeringo@deciphera.com

Products or Services

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

DSS, Inc.

dss_sq_logo

About Us


12575 Us Hwy 1
Suite 200
Juno Beach, FL 33408
(561) 284-7000

Primary Contacts

Rob Gill
Strategic Federal Account Manager
(561) 629-3605
rgill@dssinc.com

Eisai Inc.

eisai_sq_logo

About Us

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.


200 Metro Blvd
Nutley, AK 07110
(214) 586-6800
eisai.com

Primary Contacts

Jeff Granberry
Director Federal Markets
(214) 505-5584
jeffrey_granberry@eisai.com

Dr. Christine Divers, PhD
Director, US Field Health Econ & Outcome Research and Real World Evidence Eisai Inc
(551) 502-1029
Christine_divers@eisai.com

Eli Lilly & Company

lilly_sq_logo

About Us

Lilly unites caring with discovery to create medicines that make life better for people around the world.


Lilly Corporate Center
893 Delaware St
Indianapolis, IN 46225
(317) 292-2975
lilly.com

Primary Contacts

Aeron P. Burns
Regional Oncology Account Manager
(317) 292-2975
burns_aeron_p@lilly.com

Amine Ale-Ali
National Oncology Outcomes Liaison
(619) 496-6498
a_ale_ali@lilly.com

Products or Services

Patient educational materials for all promoted products.

Exelixis

t_062117

About Us

We are shaping the future of oncology for patients.


1851 Harbor Bay Parkway
Alameda, CA 94502
(503) 804-5087
cabometyxhcp.com

Primary Contacts

Joan Gratton
Senior Director National Accounts - Federal
(503) 804-5087
jgratton@exelixis.com

Tasha Hall
Medical Director
(412) 680-5256
thall@exelixis.com

Products or Services

cabozantinib has 3 indications in:
* Advanced RCC: In combination with nivolumab to treat renal cell carcinoma (RCC) that has spread (advanced RCC), and you have not already had treatment for your advanced RCC
Alone to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC)

* 2nd line HCC

* DTC:Adults and children 12 years of age and older who have a type of thyroid cancer called differentiated thyroid cancer (DTC) that has spread (locally advanced or metastatic), and,
has progressed after treatment with a VEGFR-targeted treatment, and
your DTC can no longer be treated with radioactive iodine, or you are not able to receive radioactive iodine treatment.

Foundation Medicine

foundationmedicine_sq_logo

About Us


400 Summer Street
Boston, MA 02210
(888) 988-3639
foundationmedicine.com

Primary Contacts

Andy Fedor
Federal Account Director
(614) 226-3082
afedor@foundationmedicine.com

Genmab

Genmab-Logo

About Us

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases.


777 Scudders Mill Road
Bldg 2, Floor 4
Plainsboro, NJ 08536
(609) 430-2481
genmab.com

Primary Contacts

Elizabeth Morse
Director, Federal National Accounts
(630) 386-1633
elmo@genmab.copm

Gia McLean
Associate Director, Health Evidence Outcomes Research
(640) 230-2647
gimc@genmab.com

Products or Services

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics.

For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on X.com/Genmab.

EPKINLY® (USA, Japan)

Epcoritamab
Disease area: Oncology

Gilead Sciences

gilead_sq_logo

About Us

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.


333 Lakeside Drive
Foster City, CA 94404
(650) 574-3000
gilead.com

Primary Contacts

David Baran
Senior Director, National Federal Accounts, Market Access
(630) 209-0588
david.baran@gilead.com

Chase Williams, PharmD., MBA
Principal Medical Scientist
(708) 288-5140
chase.williams@gilead.com

Incyte Corporation

Incyte_logo.svg

About Us

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.


1801 Augustine Cut-Off
Wilmington, DE 19803
(855) 446-2983
Incyte.com

Primary Contacts

Brian Gaughran
Field Associate Director, Government and Strategic Accounts
(516) 246-4129
bgaughran@incyte.com

Anthony Duca
Senior Director, Government Accounts
(609) 694-5427
aduca@incyte.com

Products or Services

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.

Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. We are creating a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists.

J&J Innovative Medicine

jnj_sq_logo

About Us

Veteran's unique health journeys inspire us to lead where medicine is going.


One Johnson and Johnson Plaza
New Brunswick, NJ 08903
(732) 524-0400
jnj.com

Primary Contacts

Karen Watkins
Federal Account Director
(585) 478-8968
Kwatkin1@its.jnj.com

Brian Macomson
Scientific Director
(706) 469-0904
bmacoms1@its.jnj.com

Products or Services

We aspire to develop breakthrough treatments to transform the future of health, discovering new pathways and modalities to be in front of diseases and aspiring to find cures. We are also expanding access to our medicines and developing tools and programs so patients can receive optimal care.

We do this by reimagining how we discover and develop transformational treatments, accelerating the path from lab to life through data and technology, and advocating for patients every step of the way.

Patients will always inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we will continue to confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow.

Kite Pharma

NEW COLOR LOGO

About Us

At Kite, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit.

We believe cell therapy has the ability to change the way cancer is treated. Our industry-leading cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells.


2400 Broadway
Santa Monica, CA 90404
(310) 824-9999
kitepharma.com

Primary Contacts

Lisa Zuccarello, MHA
Director, US Health Systems
(732) 547-3868
lzuccarello@kitepharma.com

Ima Garcia
Director East, MSL Team
(312) 890-6774
igarcia1@kitepharma.com

Mallinckrodt

Mallinckrodt_sq_logo

About Us


1531 Evanvale Dr
Allen, TX 75013
(214) 543-4078
mallinckrodt.com

Primary Contacts

Jeremy Huff
Director of Government Programs
(214) 543-4078
jhuff00@gmail.com

Menarini Stemline

menarini_sq_logo

About Us

To build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and marketing innovative oncology therapeutics that target difficult-to-treat cancers.


750 Lexington Avenue, 11th Floor
New York, NY 10022
(410) 271-2322
stemline.com

Primary Contacts

William Gardner
Senior Director National Payer Accounts
(410) 271-2322
bgardner@menarinistemline.com

Eric Kruep
Executive Director, Clinical & Value Evidence Liaison
(813) 732-9592
ekruep@menarinistemline.com

Products or Services

Stemline is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by cancer.

Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.

The information in the table reflects Stemline’s development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.

Mirati

mirati_sq_logo

About Us

We are a targeted oncology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. Unified for patients, our vision is to unlock the science behind the promise of a life beyond cancer.


3545 Cray Ct
San Diego, CA 92121
(844) 647-2841
mirati.com

Primary Contacts

Trebla Grant
National Access Director
(281) 210-4303
GrantT@mirati.com

Anna Vasyman
Regional Health Outcomes Director
(847) 293-9776
VaysmanA@mirati.com

Products or Services

The Mirati & Me Patient Support Program offers comprehensive support services for eligible patients, caregivers, and healthcare professionals, including personalized education and financial resources to help patients who have been prescribed Mirati medications start and stay on treatment as directed by their physician.

Pfizer Oncology

Office_of_the_CEO_Signature_Color_RGB

About Us

To become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live.

Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; Integrative Biotechnology; and Immuno- Oncology.


66 Hundson Boulevard East
New York, NY 10001
(800) 879-3477
cancer.pfizer.com

Primary Contacts

Marc Miller
Federal Account Director
(571) 375-6471
marc.miller@pfizer.com

Ali Whitmer
Field Medical Outcomes Director
(314) 281-9861
alison.whitmer@pfizer.com

Pharmacyclics LLC, an AbbVie Company

pharmacyclics_sq_logo

About Us

Pharmacyclics is an AbbVie company based in the Bay Area, California. Our charge is to help people impacted by cancer and immune-mediated diseases by focusing on the development of safe and effective treatment options. We will know that our mission has been achieved when patients and their families have rediscovered the Magic of Normal – where disease no longer defines the every day.


1000 Gateway Blvd
South San Francisco, CA 94080
(408) 215-3000
pharmacyclics.com

Primary Contacts

James Byrd
Federal Account Executive
(443) 926-6016
jbyrd@pcyc.com

Jill Drury
National Medical Outcomes and Science Liaison
(847) 935-8089
jill.drury@abbvie.com

Sun Pharmaceutical Industries

Sun_Pharma

About Us

Over the last two decades, Sun Pharma has established itself as a leading player in the generics market in the U.S. We are a leading specialty generics pharmaceutical company in the U.S. and are ranked 2nd by prescriptions in the U.S. dermatology market. We are rapidly ramping up our presence in the specialty branded market, with dermatology, ophthalmology and oncology as key target segments. Our U.S. headquarters is in Princeton, New Jersey, with distribution, manufacturing and R&D teams at multiple locations across the country.


2 Independence Way
Princeton, NJ 08540
(609) 720-9200
sunpharma.com/usa

Primary Contacts

Heather Rosati
National Account Director
(757) 572-7076
heather.rosati@sunpharma.com

Kunal Patel
Medical Director, Medical Affairs
(908) 936-6379
kunal.patel@sunpharma.com

Products or Services

ODOMZO® (sonidegib) is a prescription medicine used to treat adults with basal cell carcinoma, that has come back following surgery or radiation or that cannot be treated with surgery or radiation. https://www.odomzo.com/hcp

YONSA® (abiraterone acetate) in combination with methylprednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). https://www.yonsarx.com/

Scroll To Top